Inscriere cercetatori

Asociatia Ad Astra a cercetatorilor romani lanseaza BAZA DE DATE A CERCETATORILOR ROMANI DIN DIASPORA. Scopul acestei baze de date este aceea de a stimula colaborarea dintre cercetatorii romani de peste hotare dar si cu cercetatorii din Romania. Cercetatorii care doresc sa fie nominalizati in aceasta baza de date sunt rugati sa trimita un email la

Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase

Domenii publicaţii > Ştiinţe medicale + Tipuri publicaţii > Articol în revistã ştiinţificã

Autori: Moldoveanu E, Mut-Vitcu B, Tanaseanu GR, Marta DS, Manea G, Kosaka T, Vidulescu C, Tanaseanu C

Editorial: Clinical Biochemistry doi:10.1016/j.clinbiochem.2008.09.109 , 41(18), p.1429-1433, 2008.


Objective: The aim of this study was to find a pre-interventional marker with the capacity to predict in-stent restenosis (ISR). Considering the
anti-atherosclerotic role of adiponectin (APO), an adipocytokine with anti-inflammatory, anti-proliferative, anti-oxidative and anti-thrombotic
properties, low plasma levels of APO might be correlated with the risk of ISR. We investigated the correlations between the plasma levels of APO
and two markers of inflammation: lipoprotein associated phospholipase A2 (Lp-PLA2) and myeloperoxidase (MPO).
Design and methods: 80 patients with angiographically significant stenosis underwent percutaneous coronary intervention (PCI) with bare
metal stent. Plasma APO concentration and plasma Lp-PLA2 and MPO activities were evaluated immediately before and after PCI, then followedup
at 24, 48, 72 h, and at 1, 3, 6 months, respectively. ISR was evaluated at 6 months after stenting by follow-up coronary angiograms, and it was
defined as N50% stenosis of the target lesion.
Results: ISR was present in 33.75% of patients. Baseline APO plasma concentration, measured before PCI, was lower in ISR patients than those
without ISR [3.97 (±1.05) vs 6.65 (±2.95) μg/mL respectively, pb0.001]. The patients with APO values less than 4.9 μg/mL at discharge were more
susceptible to develop ISR (odd ratio, 4.27; 95% CI, 1.56–11.72, pb0.001). ISR rate was independent of inflammation markers Lp-PLA2 and MPO
baseline values, measured before PCI.
Conclusions: The persistence of a low APO plasma level at discharge and 6 months afterwards may be used as a clinically useful marker for
ISR prediction in patients undergoing PCI.

Cuvinte cheie: In-stent restenosis; Adiponectin; Lipoprotein associated phospholipase A2; Myeloperoxidase

URL: doi:10.1016/j.clinbiochem.2008.09.109